Clinical Trials

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04628767 2026-03-18

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

249 enrolled

Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT05411094 2026-03-18

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

18 enrolled

Pancreatic Neoplasms

NCT06058377 2026-03-18

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT06498635 2026-03-18

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07195695 2026-03-18

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05198830 2026-03-17

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

42 enrolled

Adenocarcinoma of Lung, Lung Neoplasms

NCT07221253 2026-03-17

AB02

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06667908 2026-03-16

CONVERGE

130 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06780137 2026-03-16

MK-6070-002

Phase 1/2 Recruiting

262 enrolled

Small Cell Lung Carcinoma

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06287775 2026-03-12

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Phase 1/2 Recruiting

45 enrolled

Lung Neoplasms

NCT05061550 2026-03-11

NeoCOAST-2

630 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05632809 2026-03-11

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

39 enrolled

Lung Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Phase 1 Recruiting

20 enrolled

Gastroesophageal Adenocarcinoma

NCT06728410 2026-03-09

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

38 enrolled

Cholangiocarcinoma

NCT06859684 2026-03-09

HAIC-quad

25 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05696782 2026-03-06

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

49 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06890598 2026-03-03

SUNRAY-02

700 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06992609 2026-03-02

ALBORAN

70 enrolled

Small Cell Lung Carcinoma

NCT06773910 2026-02-27

TIGOS-LS

250 enrolled

Limited Stage Small Cell Lung Cancer

NCT07005128 2026-02-27

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT03942328 2026-02-24

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Phase 1/2 Recruiting

85 enrolled

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT06282575 2026-02-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04379596 2026-02-23

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05211895 2026-02-23

PACIFIC-8

860 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06960577 2026-02-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

51 enrolled

Lung Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

55 enrolled

Carcinoma, Hepatocellular

NCT06467357 2026-02-17

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT07149363 2026-02-17

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

65 enrolled